← Back to Search

Monoclonal Antibodies

PIPE-307 for Multiple Sclerosis (VISTA Trial)

Phase 2
Recruiting
Research Sponsored by Pipeline Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Male or female 18 to 50 years of age, inclusive, at the first Screening visit.
A diagnosis of relapsing-remitting multiple sclerosis (RRMS) according to the 2017 Revised McDonald Criteria.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from baseline to week 26 (end of treatment period)

Summary

This trial is testing a new drug called PIPE-307 to see if it can help people with relapsing-remitting multiple sclerosis. The drug likely works by calming the immune system to prevent nerve damage. The study will compare two different doses of PIPE-307 over several months.

Who is the study for?
This trial is for English-speaking adults aged 18 to 50 with relapsing-remitting multiple sclerosis, as per the Revised McDonald Criteria. Participants must have been on a stable dose of one MS drug for the past six months and agree to use effective contraception. They should be in good health aside from MS.
What is being tested?
The study tests PIPE-307 at two different doses against a placebo in people with relapsing-remitting multiple sclerosis. It's randomized and double-blind, meaning neither participants nor researchers know who gets which treatment, divided into three groups equally over about 30 weeks.
What are the potential side effects?
While specific side effects are not listed here, clinical trials like this monitor for any adverse reactions ranging from mild symptoms such as headaches or nausea to more serious ones related to organ function or immune response.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 50 years old.
Select...
I have been diagnosed with relapsing-remitting MS according to the latest criteria.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline to week 26 (end of treatment period)
This trial's timeline: 3 weeks for screening, Varies for treatment, and from baseline to week 26 (end of treatment period) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Treatment-emergent adverse events (TEAE)

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: PIPE-307 Dose BExperimental Treatment1 Intervention
Group II: PIPE-307 Dose AExperimental Treatment1 Intervention
Group III: PlaceboPlacebo Group1 Intervention

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Multiple Sclerosis (MS) treatments primarily work by modulating the immune system to reduce inflammation and prevent further damage to the nervous system. For example, dimethyl fumarate (BG-12) activates the Nrf2 pathway, which reduces oxidative stress and inflammation, while glatiramer acetate mimics myelin basic protein, distracting the immune system from attacking myelin. These mechanisms are crucial for MS patients as they help to decrease the frequency of relapses, slow disease progression, and reduce the formation of new brain lesions, thereby improving overall quality of life.
Oral drugs in multiple sclerosis therapy: an overview and a critical appraisal.Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.

Find a Location

Who is running the clinical trial?

Pipeline Therapeutics, Inc.Lead Sponsor
4 Previous Clinical Trials
160 Total Patients Enrolled
3 Trials studying Multiple Sclerosis
132 Patients Enrolled for Multiple Sclerosis
Contineum TherapeuticsLead Sponsor
4 Previous Clinical Trials
160 Total Patients Enrolled
3 Trials studying Multiple Sclerosis
132 Patients Enrolled for Multiple Sclerosis
Stephen Huhn, MDStudy DirectorContineum Therapeutics
8 Previous Clinical Trials
213 Total Patients Enrolled
2 Trials studying Multiple Sclerosis
126 Patients Enrolled for Multiple Sclerosis
~76 spots leftby Aug 2025